Module 3: Study Planning & Communications
Study Planning and Communications describes how to optimize the study question, design, and communications for diversity, equity, and inclusion in cancer clinical research. The impact of study design, eligibility criteria, feasibility assessment, site selection, decentralization of trials, and health literate and linguistically appropriate communications on recruitment and retention of underrepresented populations are discussed.
Original Release Date: July 15, 2022
Expiration Date: August 15, 2024
Review Date: August 10, 2023 by Willyanne Decormier Plosky, DrPH
This activity is intended for leadership, investigators, practicing providers, clinical trialists, clinical trial staff, nurse practictioners, nurses, research nurse specialists, physician assistants, clinical research coordinators, other frontline staff, regulatory and IRB committee members, and others who design, conduct, report or are responsible for clinical research.
Upon completion of this activity, participants will be able to:
- Appreciate importance of optimizing the study planning and design for DEI in clinical research, and specifically for cancer clinical research
- Understand how study design, through eligibility criteria, feasibility assessments, site selection, and communications, can impact recruitment of underrepresented populations
PLEASE NOTE: For questions or assistance with any special needs regarding the training course, please contact the MRCT Center at: MRCT@bwh.harvard.edu
YOU MAY ALSO BE INTERESTED IN Interpretation and Application of ICH E6(R2)
Welcome to Version 1.0 of Interpretation and Application of ICH E6(R2) – an online course developed by the MRCT Center with a multi-stakeholder international team of experts.
MANY THANKS TO THE FOLLOWING PEOPLE FOR ACTING AS DISCUSSANTS DURING THIS TRAINING SERIES:
Dr. Nadine J. McCleary, Medical Oncologist, Department of Medical Oncology in the Center for Gastrointestinal Oncology, the Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
Dr. Lindsay McNair, Chief Medical Officer, WIRB-Copernicus Group (WCG)
This activity is not for credit.